ClinicalTrials.gg
CompletedNCT00201981Updated Jun 15, 2026

A 1-Year Study in Multiple Clinics Testing Rebamipide Eye Drops for Dry Eye Compared With a Placebo

A Phase 3 interventional study of Rebamipide 1% and Rebamipide 2% in Keratoconjunctivitis Sicca, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 63 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled May 2004, registered Sep 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
755
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies in Keratoconjunctivitis Sicca with a site in United States — none open to participants now, none under way, none of them phase 3. Keratoconjunctivitis Sicca · United States.

Enrollment
4th of 52
755 · median 100
Started
2004
with 3 others
Phase 3
13 of 56
none open now
Registered
4th of 56
by date
Lead sponsor
2 of 56
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 56 studies in Keratoconjunctivitis Sicca with a site in United States, this one is the 4th largest by enrollment of the 52 interventional ones that give a count, is one of 4 that started in 2004, is one of 13 in phase 3, and was the 4th registered.

Keratoconjunctivitis Sicca

85 studies on the registry are indexed under Keratoconjunctivitis Sicca; 1 is open to participants now.

Browse Keratoconjunctivitis Sicca studies →

Open to participants now

None of the 56 studies in Keratoconjunctivitis Sicca with a site in United States is open now. The open studies under Keratoconjunctivitis Sicca, anywhere →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 56 studies in Keratoconjunctivitis Sicca with a site in United States as a file.
02

Study summary

The purpose of this study is to determine the potential safety and effectiveness of rebamipide eye drops, an investigational eye drop being developed for the treatment of keratoconjunctivitis sicca (dry eye).

Read the detailed description

There is a need for effective therapy for dry eye that treats the underlying cause of the syndrome. The goal of this study is to assess the impact of rebamipide on dry eye symptom.

03

Conditions studied

  • Keratoconjunctivitis Sicca

Keywords

  • dry eye
  • keratoconjunctivitis sicca
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • must have symptoms of dry eye for a minimum of 6 months
  • must be able to sign and date an

Exclusion criteria

Exclusion Criteria:

  • presence of anterior segment disease
  • glaucoma or ocular hypertension
  • using Restasis
  • use of topically instilled ocular medications during study
  • use of contact lenses
  • history of ocular surgery within 12 months
  • females who are pregnant, breast feeding, or and not willing to remain abstinent or use
  • presence of Stevens-Johnson syndrome
  • any anticipated change in medication through-out study
  • concurrent involvement in another study or previous receipt of this drug
  • cannot be safely be weaned off of ocular medications
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
755 participants (actual)

Study arms

  • Active comparator
    Rebamipide 1%

    Participants will receive rebamipide 1% ophthalmic suspension four times daily (QID) for 52 weeks

    Drug: Rebamipide 1%

  • Active comparator
    Rebamipide 2%

    Participants will receive rebamipide 2% ophthalmic suspension four times daily (QID) for 52 weeks

    Drug: Rebamipide 2%

  • Placebo comparator
    Placebo

    Participants will receive a rebamipide-matching placebo ophthalmically four times daily (QID) for 52 weeks.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. fluorescein corneal staining (FCS) total score at week 12 and the average primary ocular discomfort (POD) severity score at week 12

    Time frame: 12 week and 26 week

Secondary outcomes

  1. fluorescein corneal staining (FCS) total score at week 26 and the average primary ocular discomfort (POD) severity score at week 26

    Time frame: 12 week and 26 week

07

Study locations

63 sites
  • Alabama Research Center, LLC
    Birmingham, Alabama 35209, United States
  • Sun Valley Arthritis Center, Ltd.
    Glendale, Arizona 85308, United States
  • Pivotel Research Center
    Peoria, Arizona 85381, United States
  • Hope research Institute
    Phoenix, Arizona 85006, United States
  • Buena Vista Eye Care Center
    Phoenix, Arizona 85012, United States
  • Radiant Research
    Scottsdale, Arizona 85251, United States
  • Sall Eye Research Center
    Artesia, California 90701-5653, United States
  • Radiant Research - Irvine
    Irvine, California 92618, United States
  • Scripps Clinic Medical Group, Inc.
    La Jolla, California 92037, United States
  • American Eye Institute
    Los Angeles, California 90048, United States
  • Eye Clinic of San Diego
    San Diego, California 92103, United States
  • Healthcare Partners Medical Group
    Torrance, California 90503, United States
  • Centennial Eye Associates
    Centennial, Colorado 80112, United States
  • Corneal Consultants of Colorado
    Littleton, Colorado 80120, United States
  • Western States Clinical Research, Inc.
    Wheat Ridge, Colorado 80033, United States
  • Peter C. Donshik, MDPC
    Bloomfield, Connecticut 06002, United States
  • Opticare Eye Health Center
    Waterbury, Connecticut 06708, United States
  • The Eye Associates
    Bradenton, Florida 34209, United States
  • Hernando Eye Institute
    Brooksville, Florida 34613, United States
  • Radiant Research, Inc. - Lake Worth
    Lake Worth, Florida 33461, United States
  • Suncoast Clinical Research, Inc.
    New Port Richey, Florida 34652, United States
  • Eye Associates International
    Ormond Beach, Florida 32174, United States
  • Pinellas Eye Center
    Pinellas Park, Florida 33781, United States
  • Ft. Lauderdale Eye Institute
    Sunrise, Florida 33351, United States
  • Marvin E. Greenberg, MD PA 7
    Tamarac, Florida 33321, United States
  • Clinical Research of West Florida, Inc.
    Tampa, Florida 33603, United States
  • International Eye Center
    Tampa, Florida 33603, United States
  • Omni Eye Services
    Atlanta, Georgia 30342, United States
  • University of Kentucky, Department of Ophthamology
    Lexington, Kentucky 40536-0293, United States
  • Kentucky Lions Eye Center
    Louisville, Kentucky 40222, United States
  • Gulf Coast Research Associates, Inc.
    Baton Rouge, Louisiana 70808, United States
  • Danial Long, MD
    Gretna, Louisiana 70056, United States
  • Lakeview Optical
    New Orleans, Louisiana 70124, United States
  • Eye Center Northeast
    Bangor, Maine 04401, United States
  • Krieger Eye Institute
    Baltimore, Maryland 21215, United States
  • The Wilmer Eye Institute
    Lutherville, Maryland 21093, United States
  • New England Eye Center
    Boston, Massachusetts 02111, United States
  • The Eye Institute - Lahey Clinic North
    Peabody, Massachusetts 01960, United States
  • Mississippi Eye Associates
    Ocean Springs, Mississippi 39564, United States
  • Montana Medical Research, LLC
    Missoula, Montana 59804, United States
  • Clinical Research Center of Nevada
    Las Vegas, Nevada 89104, United States
  • Eye Associates of New Mexico
    Albuquerque, New Mexico 87109, United States
  • Western New York Eye Center
    Orchard Park, New York 14127, United States
  • Glaucoma Consultants of the Capital Region
    Slingerlands, New York 12159, United States
  • Orellana Retina Associates, PLLC
    Raleigh, North Carolina 27612, United States
  • University Hospitals of Cleveland
    Cleveland, Ohio 44106-5068, United States
  • Comprehensive Opthalmology & Optical Services
    Cleveland, Ohio 44115, United States
  • Clinical Research Source, Inc.
    Perrysburg, Ohio 43551, United States
  • Clinical Research Institute of Southern Oregon
    Medford, Oregon 97504, United States
  • Northwest Corneal Services
    Portland, Oregon 97223, United States
  • Vision Surgery and Laser Center
    Roseburg, Oregon 97470, United States
  • West Hills Vision Center
    Moon Township, Pennsylvania 15108, United States
  • Glaucoma Consultants and Center for Eye Research
    Mt. Pleasant, South Carolina 29464, United States
  • University Eye Surgeons
    Maryville, Tennessee 37803, United States
  • St. Luke's Eye Institute
    Amarillo, Texas 79106, United States
  • Eye Clinic of Austin
    Austin, Texas 78731, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Surgical Eye Associates, PA
    Houston, Texas 77055, United States
  • Brazosport Eye Institute
    Lake Jackson, Texas 77566, United States
  • Axia Research
    Salt Lake City, Utah 84107, United States
  • John Moran Eye Center, University of Utah
    Salt Lake City, Utah 84132, United States
  • Physicians Research Options, LC
    Sandy City, Utah 84070, United States
  • Access Eye Research Center
    Fredericksburg, Virginia 22405, United States
08

References and documents

Publications

  • Yamasaki K, Ishiyama H, Imaizumi T, Kanbe T, Yabuuchi Y. Effect of OPC-12759, a novel antiulcer agent, on chronic and acute experimental gastric ulcer, and gastric secretion in rats. Jpn J Pharmacol. 1989 Apr;49(4):441-8. doi: 10.1254/jjp.49.441. PubMed 2542684 ↗
  • Yamasaki K, Kanbe T, Chijiwa T, Ishiyama H, Morita S. Gastric mucosal protection by OPC-12759, a novel antiulcer compound, in the rat. Eur J Pharmacol. 1987 Oct 6;142(1):23-9. doi: 10.1016/0014-2999(87)90649-2. PubMed 3480223 ↗
  • Yoshikawa T, Naito Y, Tanigawa T, Kondo M. Free radical scavenging activity of the novel anti-ulcer agent rebamipide studied by electron spin resonance. Arzneimittelforschung. 1993 Mar;43(3):363-6. PubMed 8387788 ↗
  • Yoshikawa T, Naito Y, Nakamura S, Nishimura S, Kaneko T, Iinuma S, Takahashi S, Kondo M, Yamasaki K. Effect of rebamipide on lipid peroxidation and gastric mucosal injury induced by indometacin in rats. Arzneimittelforschung. 1993 Dec;43(12):1327-30. PubMed 8141822 ↗
  • Yamasaki K, et al. Effect of OPC 12759 on the production of oxygen-derived free radical from human polymorphonuclear leukocytes. In-house Report No. 004272.
  • Yamasaki K, et al. Effect of OPC 12759 on gastric mucosal blood flow in rats-determination by the hydrogen gas clearance method. In-house Report No. 003915.
  • Imaizumi, T, et al. Effect of OPC 12759 and cetraxate on gastric mucosal hemodynamics and oxygen sufficiency in rats-analysis by reflectance spectrophotometry. In-house Report No. 004101.
  • Garcher C, Bron A, Baudouin C, Bildstein L, Bara J. CA 19-9 ELISA test: a new method for studying mucus changes in tears. Br J Ophthalmol. 1998 Jan;82(1):88-90. doi: 10.1136/bjo.82.1.88. PubMed 9536889 ↗
  • Danjo Y, Watanabe H, Tisdale AS, George M, Tsumura T, Abelson MB, Gipson IK. Alteration of mucin in human conjunctival epithelia in dry eye. Invest Ophthalmol Vis Sci. 1998 Dec;39(13):2602-9. PubMed 9856770 ↗
  • Pflugfelder SC, Tseng SC, Yoshino K, Monroy D, Felix C, Reis BL. Correlation of goblet cell density and mucosal epithelial membrane mucin expression with rose bengal staining in patients with ocular irritation. Ophthalmology. 1997 Feb;104(2):223-35. doi: 10.1016/s0161-6420(97)30330-3. PubMed 9052626 ↗
  • Kinoshita S, Kiorpes TC, Friend J, Thoft RA. Goblet cell density in ocular surface disease. A better indicator than tear mucin. Arch Ophthalmol. 1983 Aug;101(8):1284-7. doi: 10.1001/archopht.1983.01040020286025. PubMed 6882259 ↗
  • Rivas L, Oroza MA, Perez-Esteban A, Murube-del-Castillo J. Morphological changes in ocular surface in dry eyes and other disorders by impression cytology. Graefes Arch Clin Exp Ophthalmol. 1992;230(4):329-34. doi: 10.1007/BF00165940. PubMed 1505763 ↗
  • Nelson JD, Wright JC. Conjunctival goblet cell densities in ocular surface disease. Arch Ophthalmol. 1984 Jul;102(7):1049-51. doi: 10.1001/archopht.1984.01040030851031. PubMed 6378156 ↗
  • Ferris FL 3rd, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol. 1982 Jul;94(1):91-6. PubMed 7091289 ↗
  • Lemp MA. Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. CLAO J. 1995 Oct;21(4):221-32. No abstract available. PubMed 8565190 ↗
  • Gail M, Simon R. Testing for qualitative interactions between treatment effects and patient subsets. Biometrics. 1985 Jun;41(2):361-72. PubMed 4027319 ↗
  • Davis CS, Chung Y. Randomization model methods for evaluating treatment efficacy in multicenter clinical trials. Biometrics. 1995 Sep;51(3):1163-74. PubMed 7548700 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2004 to primary completion in Feb 2007, 33 months.

Of 12 phase 3 interventional studies under Keratoconjunctivitis Sicca, half reached primary completion within 14 months of starting (the median); a quarter within 7 and three quarters within 18. This study's 33 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 20, 2005
StartActual
May 1, 2004
Primary completionActual
Feb 1, 2007
CompletionActual
Feb 1, 2007
Results delay requested
Feb 19, 2014
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00201981
Collaborators
Novartis
Responsible party
Sponsor
First posted
Sep 20, 2005
Start date
May 1, 2004
Primary completion
Feb 1, 2007
Completion
Feb 1, 2007
Last update
Jun 15, 2026

Study contacts

Gary Foulks, MD
study chair · University of Louisville
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rebamipide

Start the discussion